| Literature DB >> 35545176 |
David S Ettinger1, Douglas E Wood2, Dara L Aisner3, Wallace Akerley4, Jessica R Bauman5, Ankit Bharat6, Debora S Bruno7, Joe Y Chang8, Lucian R Chirieac9, Thomas A D'Amico10, Malcolm DeCamp11, Thomas J Dilling12, Jonathan Dowell13, Scott Gettinger14, Travis E Grotz15, Matthew A Gubens16, Aparna Hegde17, Rudy P Lackner18, Michael Lanuti19, Jules Lin20, Billy W Loo21, Christine M Lovly22, Fabien Maldonado22, Erminia Massarelli23, Daniel Morgensztern24, Thomas Ng25, Gregory A Otterson26, Jose M Pacheco3, Sandip P Patel27, Gregory J Riely28, Jonathan Riess29, Steven E Schild15, Theresa A Shapiro1, Aditi P Singh30, James Stevenson7, Alda Tam8, Tawee Tanvetyanon12, Jane Yanagawa31, Stephen C Yang1, Edwin Yau32, Kristina Gregory33, Miranda Hughes33.
Abstract
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. Patients with metastatic lung cancer who are eligible for targeted therapies or immunotherapies are now surviving longer. This selection from the NCCN Guidelines for NSCLC focuses on targeted therapies for patients with metastatic NSCLC and actionable mutations.Entities:
Mesh：
Year: 2022 PMID： 35545176 DOI： 10.6004/jnccn.2022.0025
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908